Common Contracts
958 similar Underwriting Agreement contracts by Beta Bionics, Inc., Trevi Therapeutics, Inc., Amerant Bancorp Inc., others
Caris Life Sciences, Inc. (a Texas corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 9th, 2025 • Caris Life Sciences, Inc. • Services-medical laboratories • New York
Trevi Therapeutics, Inc. (a Delaware corporation) 17,400,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 4th, 2025 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • New York
Underwriting AgreementUnderwriting Agreement • June 2nd, 2025 • Femasys Inc • Surgical & medical instruments & apparatus • New York
ELBIT SYSTEMS LTD. (a corporation incorporated under the laws of the State of Israel) 1,365,450 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 23rd, 2025 • Elbit Systems LTD • Aircraft parts & auxiliary equipment, nec • New York
Elbit Systems Ltd., a corporation domiciled and incorporated in Israel (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA is acting as representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of ordinary shares, par value 1.0 NIS per share, of the Company (“Ordinary Shares”) set forth in Schedule A and B-1 hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 204,817 additional Ordinary Shares. The aforesaid 1,365,450 Ordinary Shares (the “Initial Securities”) to be purchased by the Underwrit
Exagen Inc. 3,350,000 Shares Common Stock Underwriting AgreementUnderwriting Agreement • May 8th, 2025 • Exagen Inc. • Services-medical laboratories • New York
Independent Bank Corp.Underwriting Agreement • March 25th, 2025 • Independent Bank Corp • State commercial banks • New York
Independent Bank Corp., a Massachusetts corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A hereto (the “Underwriters”) pursuant to the terms set forth herein (this “Agreement”) $300,000,000 aggregate principal amount of the Company’s 7.25% Fixed-to-Floating Rate Subordinated Notes due 2035 (the “Securities”). The Securities will be issued pursuant to an indenture, to be dated as of the Closing Date (as defined below) (the “Base Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a supplemental indenture thereto relating to the Securities, to be dated as of the Closing Date, between the Company and the Trustee (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”). Keefe, Bruyette & Woods, Inc. (“KBW”) and Piper Sandler & Co. (“Piper Sandler”) have agreed to act as representatives of the several Underwriters (in such capacity,
a Delaware corporation) 2,808,988 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 13th, 2025 • Tarsus Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with Goldman Sachs & Co. LLC (“Goldman”), BofA Securities, Inc. (“BofA”), Barclays Capital Inc. (“Barclays”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Goldman, BofA and Barclays are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 421,348 additional shares of Common Stock. The aforesaid 2,
MINERALYS THERAPEUTICS, INC. (a Delaware corporation) 12,962,962 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 12th, 2025 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • New York
Verisk Analytics, Inc. (a Delaware corporation)Underwriting Agreement • March 11th, 2025 • Verisk Analytics, Inc. • Services-computer processing & data preparation • New York
Verisk Analytics, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and HSBC Securities (USA) Inc. (“HSBC”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA and HSBC are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company, and the purchase by the Underwriters, acting severally and not jointly, of $700,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2035 (the “Securities”). The Securities will be issued pursuant to the Base Indenture, dated as of March 6, 2019 (the “Base Indenture”) between the Company and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee”), as supplemented by a Supplemental Indenture, to be dated as
Kestra Medical Technologies, Ltd. (a Bermuda exempted company) [•] of Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • February 26th, 2025 • Kestra Medical Technologies, Ltd. • Surgical & medical instruments & apparatus • New York
SELECTIVE INSURANCE GROUP, INC. (a New Jersey corporation)Underwriting Agreement • February 25th, 2025 • Selective Insurance Group Inc • Fire, marine & casualty insurance • New York
The Securities are to be issued pursuant to an indenture, dated as of February 8, 2013 (the “Base Indenture”), between the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the “Trustee”), as supplemented by a third supplemental indenture, to be dated as of February 25, 2025, between the Company and the Trustee (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”).
Oculis Holding AG (a stock corporation (Aktiengesellschaft) incorporated and existing under the laws of Switzerland) 5,000,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • February 14th, 2025 • Oculis Holding AG • Pharmaceutical preparations • New York
ZURN ELKAY WATER SOLUTIONS CORPORATION (a Delaware corporation) 7,750,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 13th, 2025 • Zurn Elkay Water Solutions Corp • General industrial machinery & equipment • New York
Underwriting AgreementUnderwriting Agreement • February 10th, 2025 • RenovoRx, Inc. • Pharmaceutical preparations • New York
TRITON INTERNATIONAL LIMITED (a Bermuda exempted company)Underwriting Agreement • February 6th, 2025 • Triton International LTD • Services-equipment rental & leasing, nec • New York
Triton International Limited, a Bermuda exempted company (the “Company”), confirms its agreement (the “Agreement”) with Morgan Stanley & Co. LLC (“Morgan Stanley”), BofA Securities, Inc. (“BofA”), RBC Capital Markets, LLC (“RBC”), UBS Securities LLC (“UBS”) and Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters named in Schedule A (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom
BETA BIONICS, INC. (a Delaware corporation) [ • ] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 28th, 2025 • Beta Bionics, Inc. • Surgical & medical instruments & apparatus • New York
METSERA, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 27th, 2025 • Metsera, Inc. • Pharmaceutical preparations • New York
BETA BIONICS, INC. (a Delaware corporation) [ • ] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 22nd, 2025 • Beta Bionics, Inc. • Surgical & medical instruments & apparatus • New York
MONOPAR THERAPEUTICS INC. (a Delaware corporation) 798,655 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 23rd, 2024 • Monopar Therapeutics • Pharmaceutical preparations • New York
INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock Warrants to Purchase Up to 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 16th, 2024 • Inovio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with Oppenheimer & Co. Inc. (“Oppenheimer”), Citizens JMP Securities, LLC (“Citizens JMP”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Oppenheimer and Citizens JMP are acting as representatives (in such capacity, the “Representatives”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of (i) an aggregate of 10,000,000 shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) in the respective amounts set forth in Schedule A hereto (the “Underwritten Shares”) and (ii) warrants (the “Warrants”) to purchase up to an aggregate of 10,000,000 shares of Common Stock in the respective amounts set forth in Schedule A hereto. The Underwritten Shares and
Trevi Therapeutics, Inc. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 16th, 2024 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • New York
JANUX THERAPEUTICS, INC. (a Delaware corporation) 5,317,460 Shares of Common Stock and Pre-Funded Warrants to Purchase 238,095 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 5th, 2024 • Janux Therapeutics, Inc. • Pharmaceutical preparations • New York
1,797,600 Shares of Class A Common Stock (Par Value $0.01 per Share) EQUITY BANCSHARES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • December 3rd, 2024 • Equity Bancshares Inc • State commercial banks • New York
Knightscope, Inc. 393,659 SHARES OF CLASS A COMMON STOCK, PAR VALUE $0.001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE 816,341 SHARES OF CLASS A COMMON STOCK, PAR VALUE $0.001 PER SHARE Underwriting AgreementUnderwriting Agreement • November 22nd, 2024 • Knightscope, Inc. • Communications equipment, nec • New York
VERRICA PHARMACEUTICALS INC. (a Delaware corporation) 44,964,045 Shares of Common Stock Warrants to Purchase 47,200,000 Shares of Common Stock (or Pre- Funded Warrants in lieu thereof) Pre-Funded Warrants to Purchase 2,235,955 Shares of Common Stock...Underwriting Agreement • November 21st, 2024 • Verrica Pharmaceuticals Inc. • Pharmaceutical preparations • New York
PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) 1,923,076 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 31st, 2024 • PROCEPT BioRobotics Corp • Surgical & medical instruments & apparatus • New York
ProQR Therapeutics N.V. 18,000,000 Ordinary Shares UNDERWRITING AGREEMENT Dated: October 22, 2024 ProQR Therapeutics N.V. 18,000,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • October 25th, 2024 • ProQR Therapeutics N.V. • Pharmaceutical preparations • New York
CAPRICOR THERAPEUTICS, INC. (a Delaware corporation) 4,412,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 17th, 2024 • Capricor Therapeutics, Inc. • Pharmaceutical preparations • New York
SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) envveno medical corporationUnderwriting Agreement • September 30th, 2024 • enVVeno Medical Corp • Surgical & medical instruments & apparatus • New York
7,900,000 Shares of Class A Voting Common Stock (Par Value $0.10 per Share) AMERANT BANCORP INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 27th, 2024 • Amerant Bancorp Inc. • National commercial banks • New York
HAWAIIAN ELECTRIC INDUSTRIES, INC. 54,054,054 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 24th, 2024 • Hawaiian Electric Co Inc • Electric services • New York
ASCENDIS PHARMA A/S (a company organized under the laws of Denmark) 2,000,000 American Depositary Shares Representing an Aggregate of 2,000,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • September 23rd, 2024 • Ascendis Pharma a/S • Pharmaceutical preparations • New York
GUARDIAN PHARMACY SERVICES, INC. (a Delaware corporation) [•] Shares of Class A Common Stock, $0.001 par value UNDERWRITING AGREEMENTUnderwriting Agreement • September 16th, 2024 • Guardian Pharmacy Services, Inc. • Retail-drug stores and proprietary stores • New York
REVIVA PHARMACEUTICALS HOLDINGS, INC. 3,276,262 OF SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE 1,485,643 SHARES OF SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE WARRANTS TO PURCHASE 4,761,905 SHARES OF...Underwriting Agreement • August 21st, 2024 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
MeiraGTx Holdings plc (a Cayman Islands exempted company) 12,500,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • August 13th, 2024 • MeiraGTx Holdings PLC • Biological products, (no disgnostic substances) • New York
MeiraGTx Holdings plc, (a Cayman Islands exempted company) (the “Company”) confirms its agreement with each of the Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA Securities, Inc. is acting as representative (in such capacity, the “Representative”), with respect to the issue and sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of ordinary shares, nominal value $0.00003881 per share, of the Company (“Ordinary Shares”) set forth in Schedule A hereto. The aforesaid 12,500,000 Ordinary Shares to be purchased by the Underwriters are herein called the “Securities.”